Cargando…
Mucin glycosylating enzyme GALNT2 suppresses malignancy in gastric adenocarcinoma by reducing MET phosphorylation
Glycosylation affects malignancy in cancer. Here, we report that N- acetylgalactosaminyltransferase 2 (GALNT2), an enzyme that mediates the initial step of mucin type-O glycosylation, suppresses malignant phenotypes in gastric adenocarcinoma (GCA) by modifying MET (Hepatocyte growth factor receptor)...
Autores principales: | Liu, Shin-Yun, Shun, Chia-Tung, Hung, Kuan-Yu, Juan, Hsueh-Fen, Hsu, Chia-Lang, Huang, Min-Chuan, Lai, I-Rue |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4905470/ https://www.ncbi.nlm.nih.gov/pubmed/26848976 http://dx.doi.org/10.18632/oncotarget.7081 |
Ejemplares similares
-
Knockdown of GALNT1 suppresses malignant phenotype of hepatocellular carcinoma by suppressing EGFR signaling
por: Huang, Miao-Juei, et al.
Publicado: (2015) -
GALNT6 expression enhances aggressive phenotypes of ovarian cancer cells by regulating EGFR activity
por: Lin, Tzu-Chi, et al.
Publicado: (2017) -
O-Glycosylating Enzyme GALNT2 Predicts Worse Prognosis in Cervical Cancer
por: Zhou, Lixia, et al.
Publicado: (2022) -
GALNT6 promotes breast cancer metastasis by increasing mucin-type O-glycosylation of α2M
por: Liu, Chang, et al.
Publicado: (2020) -
The O-glycosylating enzyme GALNT2 acts as an oncogenic driver in non-small cell lung cancer
por: Hu, Qing, et al.
Publicado: (2022)